Developer docs
API playgroundTry for free, no card

Search company profiles

ARGOBIO

Full company profile

uuid0000tw6

Namestring
ARGOBIO
Legal namestring
Argobio SAS
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech startup studio, therapeutic company creation, venture builder biotech, biotech incubation services, life sciences investment
Industry2 codes
PRIMARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
SECONDARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Investment Advice6282
Product category
Biotech Company Creation and Venture Building
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Venture Building Services
TypeLicensing Royalties
Description

ARGOBIO generates returns through equity ownership in portfolio companies it creates and co-founds. The company incubates early-stage therapeutic projects and retains ownership stakes that appreciate as portfolio companies secure subsequent funding rounds and achieve milestones.

argobiostudio.com
2Investment Syndicate Management
TypeSubscription Recurring
Description

ARGOBIO is sponsored by five strategic investors (Kurma Partners, Bpifrance, Angelini Ventures, Evotec, Institut Pasteur) who commit capital to fund company creation activities and have preferential rights to invest in portfolio companies at subsequent financing rounds.

argobiostudio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ARGOBIO is an operational venture builder that creates, incubates, and launches biotech companies from early-stage European academic research in therapeutics. It sources projects from academic partners, secures foundational IP and scientific validation, embeds experienced entrepreneurs-in-residence, and syndicates seed and Series A financing from its investor network to develop investable, de-risked biotech companies across rare diseases, neurological disorders, oncology, and immunology.

Differentiator
Functional benefit
Problem solved
Product and service8 records
1Laigo Bio
CategoryTargeted protein degradation therapeutics
Description

Biotech company pioneering proprietary SureTACs precision membrane protein degradation platform, developing targeted protein degradation therapies for oncology and immunological indications including autoimmune diseases and graft rejection.

2Crucible Therapeutics
CategoryRNA-based gene therapy for neurodegenerative diseases
Description

Biotech company developing SRSF1-targeting siRNA gene therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), spun out from the University of Sheffield's Department of Neuroscience and Sheffield Institute for Translational Neuroscience (SITraN).

3Kevad Bio
CategorySmall molecule neurology therapeutics
Description

Biotech company developing small molecule GDNF mimetics and RET tyrosine kinase activators for the treatment of Parkinson's disease and related neurodegenerative indications.

4Inverna Therapeutics
CategoryRNA splicing modulation therapeutics
Description

Danish biotech company developing RNA therapeutics using pseudo-exon splicing modulation technology, with a lead program addressing Huntington's disease and additional programs targeting LRRK2 for Parkinson's disease.

5Enodia Therapeutics
CategoryTargeted protein degradation small molecule therapeutics
Description

Biotech company developing small-molecule inhibitors of the SEC61 translocon for targeted protein degradation, leveraging machine learning-enabled selectivity modeling and proteomics-informed secretome analysis for rational drug design.

6Elkedonia
CategoryCNS neuroplastogen therapeutics
Description

Biotech company developing first-in-class, non-hallucinogenic and non-addictive neuroplastogens to address treatment-resistant depression and neuropsychiatric disorders.

7Temper Bio
CategoryAnti-inflammatory neurokine therapeutics
Description

Biotech company developing a long-acting TAFA-4 neurokine analog designed to modulate inflammation both in the circulation and the CNS, with therapeutic potential for chronic inflammatory diseases and neuro-inflammation.

8Thesian Bio
CategoryIn-vivo CAR-T cell therapy
Description

Biotech company developing cell-specific in-vivo CAR-T therapy to treat liquid and solid tumors as well as autoimmune disorders.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierSupportingTypeTechnology or Integration
Description

Life science company providing drug discovery expertise, technologies, and development partnerships. Contributes scientific capabilities and platforms to support ARGOBIO's company creation activities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Internationally renowned biomedical research center in Paris. Key academic partner providing foundational scientific discoveries for portfolio companies including Enodia Therapeutics. Supports technology transfer and company creation from its research.

3Oncode Institute
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Dutch oncology research network partnered with ARGOBIO to launch Laigo Bio. Oncode Bridge Fund and Oncology Bridge Fund provide co-funding and support company development to Series A.

argobiostudio.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partner institution for Crucible Therapeutics spinout. World-renowned Department of Neuroscience including Sheffield Institute for Translational Neuroscience (SITraN) provides foundational research for SRSF1 targeting ALS/FTD program.

5University of Southern Denmark
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Co-founder of Inverna Therapeutics. Professor Brage Storstein Andresen's laboratory provides RNA splicing modulation technology platform for Inverna's RNA therapeutics programs.

argobiostudio.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Estonian discovery-stage biotech collaborating with ARGOBIO on GDNF mimetics for Parkinson's disease. GeneCode brings small molecule RET tyrosine kinase activator technology for Kevad Bio.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research institution of Sophie Ugolini providing TAFA-4 neurokine technology for Temper Bio. Ugolini awarded 2023 Impulscience prize (€2.5M) supporting this research.

Recent move15 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based therapeutic venture builder backed by AstraZeneca, GSK, Johnson & Johnson, and Oxford/Cambridge universities. Directly comparable to ARGOBIO as an investor-operated biotech startup studio creating companies from top-tier academic research.

TypeDirect peer
Description

Evotec operates BridgeLabs, a drug discovery venture builder that creates and incubates therapeutic companies from academic research. Notable because Evotec is both an investor in ARGOBIO and a competitor pursuing similar academic-to-company translation in Europe.

3CRT Pioneer Fund
TypeDirect peer
Description

Cancer Research UK's venture builder that funds and develops oncology-focused spinouts from UK universities. Directly comparable biotech startup studio model with academic sourcing and operational company creation.

TypeDirect peer
Description

European early-stage life sciences VC firm specializing in creating and investing in biotech companies from academic research. Closely comparable investor model focused on European biotech seed and Series A opportunities.

TypeDirect peer
Description

European biotech-focused venture capital firm founded by former Index Ventures life sciences team. Similar thesis of building biotech companies from European academic science with operational support.

TypeDirect peer
Description

Sofinnova's early-stage biotech creation platform that incubates therapeutic companies from academic research before Series A. Operates a comparable model of company creation with European academic sourcing.

TypeBroad incumbent
Description

Large European life sciences VC firm with multiple funds investing across biotech stages. While not a pure venture builder like ARGOBIO, Forbion frequently co-leads ARGOBIO portfolio company rounds and shares the European biotech thesis.

TypeDirect peer
Description

Early-stage biotech investment arm of Novo Holdings focused on creating and seeding European biotech companies from academic research. Comparable investor-operator model with European focus on therapeutics.

TypeBroad incumbent
Description

Paris-based healthcare VC firm that initiated and co-founded ARGOBIO. Kurma serves as parent entity and lead investor in multiple ARGOBIO portfolio companies, with broader biotech VC activities beyond the studio model.

TypeDirect peer
Description

Oxford University spinout creation and investment firm that builds and backs deeptech and life sciences companies. Comparable startup studio model focused on translating European academic research into investable companies.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARGOBIO

Biotech Company Creation and Venture Buildingargobiostudio.com

ARGOBIO firmographics

Firmographics
Name
ARGOBIO
Legal name
Argobio SAS
Website
https://argobiostudio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ARGOBIO industry classification

Industry
Product category
Biotech Company Creation and Venture Building
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
SECONDARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)

Keywords

  • Biotech startup studio
  • Therapeutic company creation
  • Venture builder biotech
  • Biotech incubation services
  • Life sciences investment

Where ARGOBIO is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

ARGOBIO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Venture Building Services: ARGOBIO generates returns through equity ownership in portfolio companies it creates and co-founds. The company incubates early-stage therapeutic projects and retains ownership stakes that appreciate as portfolio companies secure subsequent funding rounds and achieve milestones.
  2. Investment Syndicate Management: ARGOBIO is sponsored by five strategic investors (Kurma Partners, Bpifrance, Angelini Ventures, Evotec, Institut Pasteur) who commit capital to fund company creation activities and have preferential rights to invest in portfolio companies at subsequent financing rounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

ARGOBIO product offering

Product offering

Core offering

ARGOBIO is an operational venture builder that creates, incubates, and launches biotech companies from early-stage European academic research in therapeutics. It sources projects from academic partners, secures foundational IP and scientific validation, embeds experienced entrepreneurs-in-residence, and syndicates seed and Series A financing from its investor network to develop investable, de-risked biotech companies across rare diseases, neurological disorders, oncology, and immunology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Laigo Bio Biotech company pioneering proprietary SureTACs precision membrane protein degradation platform, developing targeted protein degradation therapies for oncology and immunological indications including autoimmune diseases and graft rejection.
  • Crucible Therapeutics Biotech company developing SRSF1-targeting siRNA gene therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), spun out from the University of Sheffield's Department of Neuroscience and Sheffield Institute for Translational Neuroscience (SITraN).
  • Kevad Bio Biotech company developing small molecule GDNF mimetics and RET tyrosine kinase activators for the treatment of Parkinson's disease and related neurodegenerative indications.
  • Inverna Therapeutics Danish biotech company developing RNA therapeutics using pseudo-exon splicing modulation technology, with a lead program addressing Huntington's disease and additional programs targeting LRRK2 for Parkinson's disease.
  • Enodia Therapeutics Biotech company developing small-molecule inhibitors of the SEC61 translocon for targeted protein degradation, leveraging machine learning-enabled selectivity modeling and proteomics-informed secretome analysis for rational drug design.
  • Elkedonia Biotech company developing first-in-class, non-hallucinogenic and non-addictive neuroplastogens to address treatment-resistant depression and neuropsychiatric disorders.
  • Temper Bio Biotech company developing a long-acting TAFA-4 neurokine analog designed to modulate inflammation both in the circulation and the CNS, with therapeutic potential for chronic inflammatory diseases and neuro-inflammation.
  • Thesian Bio Biotech company developing cell-specific in-vivo CAR-T therapy to treat liquid and solid tumors as well as autoimmune disorders.

Companies that use ARGOBIO

Customer profile

Segments3 records

Ideal customer profiles3 records

ARGOBIO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

ARGOBIO partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered supporting, core and minor.

  • EvotecsupportingTechnology or IntegrationLife science company providing drug discovery expertise, technologies, and development partnerships. Contributes scientific capabilities and platforms to support ARGOBIO's company creation activities.
  • Institut PasteurcoreStrategic or Co-development PartnerInternationally renowned biomedical research center in Paris. Key academic partner providing foundational scientific discoveries for portfolio companies including Enodia Therapeutics. Supports technology transfer and company creation from its research.
  • Oncode InstitutesupportingStrategic or Co-development PartnerDutch oncology research network partnered with ARGOBIO to launch Laigo Bio. Oncode Bridge Fund and Oncology Bridge Fund provide co-funding and support company development to Series A.
  • University of SheffieldsupportingStrategic or Co-development PartnerPartner institution for Crucible Therapeutics spinout. World-renowned Department of Neuroscience including Sheffield Institute for Translational Neuroscience (SITraN) provides foundational research for SRSF1 targeting ALS/FTD program.
  • University of Southern DenmarksupportingStrategic or Co-development PartnerCo-founder of Inverna Therapeutics. Professor Brage Storstein Andresen's laboratory provides RNA splicing modulation technology platform for Inverna's RNA therapeutics programs.
  • GeneCodeminorStrategic or Co-development PartnerEstonian discovery-stage biotech collaborating with ARGOBIO on GDNF mimetics for Parkinson's disease. GeneCode brings small molecule RET tyrosine kinase activator technology for Kevad Bio.
  • CIML (Centre d'Immunologie de Marseille-Luminy)supportingStrategic or Co-development PartnerResearch institution of Sophie Ugolini providing TAFA-4 neurokine technology for Temper Bio. Ugolini awarded 2023 Impulscience prize (€2.5M) supporting this research.

Scale indicators4 records

Recent moves15 records

Expansion highlights5 records

ARGOBIO competitors and assessment

Company assessment

Direct peers

  • Apollo Therapeutics: UK-based therapeutic venture builder backed by AstraZeneca, GSK, Johnson & Johnson, and Oxford/Cambridge universities. Directly comparable to ARGOBIO as an investor-operated biotech startup studio creating companies from top-tier academic research.
  • Evotec (BridgeLabs): Evotec operates BridgeLabs, a drug discovery venture builder that creates and incubates therapeutic companies from academic research. Notable because Evotec is both an investor in ARGOBIO and a competitor pursuing similar academic-to-company translation in Europe.
  • CRT Pioneer Fund: Cancer Research UK's venture builder that funds and develops oncology-focused spinouts from UK universities. Directly comparable biotech startup studio model with academic sourcing and operational company creation.
  • BioGeneration Ventures (BGV): European early-stage life sciences VC firm specializing in creating and investing in biotech companies from academic research. Closely comparable investor model focused on European biotech seed and Series A opportunities.
  • Medicxi: European biotech-focused venture capital firm founded by former Index Ventures life sciences team. Similar thesis of building biotech companies from European academic science with operational support.
  • Sofinnova MD Start: Sofinnova's early-stage biotech creation platform that incubates therapeutic companies from academic research before Series A. Operates a comparable model of company creation with European academic sourcing.
  • Novo Seeds: Early-stage biotech investment arm of Novo Holdings focused on creating and seeding European biotech companies from academic research. Comparable investor-operator model with European focus on therapeutics.
  • Oxford Science Enterprises: Oxford University spinout creation and investment firm that builds and backs deeptech and life sciences companies. Comparable startup studio model focused on translating European academic research into investable companies.

Broad incumbents

  • Forbion: Large European life sciences VC firm with multiple funds investing across biotech stages. While not a pure venture builder like ARGOBIO, Forbion frequently co-leads ARGOBIO portfolio company rounds and shares the European biotech thesis.
  • Kurma Partners: Paris-based healthcare VC firm that initiated and co-founded ARGOBIO. Kurma serves as parent entity and lead investor in multiple ARGOBIO portfolio companies, with broader biotech VC activities beyond the studio model.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ARGOBIO social profiles

Digital presence

ARGOBIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARGOBIO leadership team

Management profile

Number of profiles

Profiles7 records

ARGOBIO funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARGOBIO M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARGOBIO

What does ARGOBIO do?

ARGOBIO is an operational venture builder that creates, incubates, and launches biotech companies from early-stage European academic research in therapeutics. It sources projects from academic partners, secures foundational IP and scientific validation, embeds experienced entrepreneurs-in-residence, and syndicates seed and Series A financing from its investor network to develop investable, de-risked biotech companies across rare diseases, neurological disorders, oncology, and immunology.

Is ARGOBIO a public or private company?

ARGOBIO is a private company. It is classified as venture growth investor backed and is currently operating.

When was ARGOBIO founded?

ARGOBIO was founded in 2021. It employs 11 to 50 people.

Where is ARGOBIO based?

ARGOBIO is headquartered in Paris, France, in the Europe region.

How does ARGOBIO make money?

Two revenue lines are on record. Venture Building Services are the primary driver. The others are investment Syndicate Management.

Who are ARGOBIO's main competitors?

Direct peers on record are Apollo Therapeutics, Evotec (BridgeLabs), CRT Pioneer Fund, BioGeneration Ventures (BGV), Medicxi, Sofinnova MD Start, Novo Seeds and Oxford Science Enterprises. Broad incumbents are Forbion and Kurma Partners.

Does ARGOBIO have an API?

No public API is recorded for ARGOBIO.

What industry is ARGOBIO in?

ARGOBIO's product category is Biotech Company Creation and Venture Building. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated), with a secondary code of FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceElkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent ChairmanElkedonia appointed Pierre d'Epenoux as Independent Chairman, bringing his experience from leading ImCheck Therapeutics, acquired by Ipsen in 2025. The company advances its first-in-class ELK1-targeting program for treatment-resistant depression, with 332 million people worldwide affected. The appointment aims to strengthen governance and strategic positioning.Labiotech.euVCs and universities: How tech transfer strengthens collaborationEuropean university spinouts in life sciences are valued at $398 billion, but universities and venture capitalists often struggle to collaborate due to differing goals and timelines. Experts note that tech transfer offices can bridge this gap, though funding remains a concern, with biopharma funding down 20% last year.BioWorldEnodia jumps ahead in Sec61 targeting, adds Kezar’s programEnodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the research of co-founder Caroline Demangel, who leads the immunobiology and therapy unit at the institute. Demangel's laboratory discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor associated with Buruli ulcers. The spinout positions Enodia in the Sec61 targeting space alongside Kezar's program.Pulse 2.0Argobio Launches Enodia With €20.7 Million Seed Round To Develop Small Molecules For Protein DegradationArgobio Studio announced the launch of Enodia Therapeutics and the completion of a €20.7 million seed financing round co-led by Elaia, Pfizer Ventures, and Bpifrance, with participation from additional investors including Institut Pasteur. The company is developing a small-molecule platform for targeted protein degradation using machine learning to selectively modulate the SEC61 translocon, with an initial focus on inflammatory and autoimmune diseases. The funding will support advancement of Enodia's lead program toward preclinical candidate selection over the next year.The Manila TimesArgobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learningEnodia Therapeutics, a biotechnology company developing small-molecule therapies for targeted protein degradation, has secured €20.7 million (US$25 million) in seed financing co-led by Elaia, Pfizer Ventures, and Bpifrance. The company was founded by Argobio Studio based on research from Institut Pasteur and uses a proprietary platform combining machine learning and proteomics to selectively modulate the SEC61 translocon for treating high-unmet-need conditions. Enodia is the third of eight companies created by Argobio to achieve seed financing in 2025.GlobeNewswireArgobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learningEnodia Therapeutics, a biotech founded by Argobio, secured €20.7 million in seed financing co-led by Elaia, Pfizer Ventures, and Bpifrance. The company develops small-molecule therapies targeting the SEC61 translocon to degrade disease proteins at synthesis. It plans to advance its lead program to preclinical candidate selection over the coming year.GlobeNewswireArgobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learningEnodia Therapeutics, a biotechnology company developing small-molecule therapies for targeted protein degradation, has secured €20.7 million (US$25 million) in seed financing co-led by Elaia, Pfizer Ventures, and Bpifrance, with participation from multiple other investors including Institut Pasteur, Wallonie Entreprendre, MACCF, InvestSud, Sambrinvest, and Mission BioCapital. The company was founded by Argobio Studio based on pioneering research from Institut Pasteur and uses a proprietary discovery platform combining machine learning and proteomics to selectively modulate the SEC61 translocon. Enodia is the third of eight companies created by Argobio to achieve seed financing in 2025.YahooArgobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learningEnodia Therapeutics, a biotechnology company developing small-molecule therapies for targeted protein degradation, secured €20.7 million (US$25 million) in seed financing co-led by Elaia, Pfizer Ventures, and Bpifrance. The company was founded by Argobio Studio based on foundational research from Institut Pasteur and uses a proprietary discovery platform combining machine learning and proteomics to modulate the SEC61 translocon. This is the third of eight companies created by Argobio to achieve seed financing in 2025, with the funding expected to progress Enodia's lead program to preclinical candidate selection.Business Wire BlogArgobio and the Institut Pasteur Launch Enodia Therapeutics: A Biotech Company With a New Approach for Targeted Protein DegradationArgobio and the Institut Pasteur launched Enodia Therapeutics, a French biotech developing small-molecule inhibitors of the Sec61/translocon complex to block and degrade disease-causing proteins. The company, which won Pfizer's BioLabs Golden Ticket award, targets cancer, inflammatory diseases, and viral infections. It is incubated by Argobio and supported by the Institut Pasteur's Innovation Accelerator.GlobeNewswireNext-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern DenmarkInverna Therapeutics, co-founded by Argobio and the University of Southern Denmark, launched as an RNA therapeutics company on January 7, 2025. Its lead program targets Huntington's disease, using sequence-based splice modulation to overcome limitations of conventional RNA therapeutics.